Primary causes of kidney disease and mortality in dialysis-dependent children.


Journal

Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728

Informations de publication

Date de publication:
05 2020
Historique:
received: 16 08 2019
accepted: 13 12 2019
revised: 09 12 2019
pubmed: 6 2 2020
medline: 27 4 2021
entrez: 6 2 2020
Statut: ppublish

Résumé

Congenital anomalies of the kidney and urinary tract (CAKUT) is associated with a slower progression to end-stage renal disease (ESRD) in pre-dialysis patients. However, little is known about the associated mortality risks after transitioning to dialysis. This retrospective cohort study included 0-21 year-old incident dialysis patients from the United States Renal Data System starting dialysis between 1995 and 2016. We examined the association of CAKUT vs. non-CAKUT with all-cause mortality, using Cox regression adjusted for case mix variables. We also examined the mortality risk associated with 14 non-CAKUT vs. CAKUT ESRD etiologies and under stratification by estimated glomerular filtration rate (eGFR). Among 25,761 patients, the median (interquartile range) age was 17 (11-19) years, and 4780 (19%) had CAKUT. CAKUT was associated with lower mortality, with an adjusted hazard ratio (aHR) of 0.72 (95%CI, 0.64-0.81) (reference: non-CAKUT). In age-stratified analyses, CAKUT vs. non-CAKUT aHRs (95%CI) were 0.66 (0.54-0.80), 0.56 (0.39-0.80), 0.66 (0.50-0.86), and 0.97 (0.80-1.18) among patients < 6, 6-< 13, 13-< 18, and ≥ 18 years at dialysis initiation, respectively. Among non-CAKUT ESRD etiologies, the risk of mortality associated with primary glomerulonephritis (aHR, 0.93; 95%CI 0.80-1.09) and focal segmental glomerulosclerosis (aHR, 0.89; 95%CI, 0.75-1.04) were comparable or slightly lower compared to CAKUT, whereas most other primary causes were associated with higher mortality risk. While the CAKUT group had lower mortality risk compared to the non-CAKUT group patients with eGFR ≥5 mL/min/1.73m CAKUT is associated with lower mortality among children < 18 years old, but showed comparable mortality with non-CAKUT among patients ≥ 18 years old. ESRD etiology should be considered in risk assessment for children initiating dialysis.

Sections du résumé

BACKGROUND
Congenital anomalies of the kidney and urinary tract (CAKUT) is associated with a slower progression to end-stage renal disease (ESRD) in pre-dialysis patients. However, little is known about the associated mortality risks after transitioning to dialysis.
METHODS
This retrospective cohort study included 0-21 year-old incident dialysis patients from the United States Renal Data System starting dialysis between 1995 and 2016. We examined the association of CAKUT vs. non-CAKUT with all-cause mortality, using Cox regression adjusted for case mix variables. We also examined the mortality risk associated with 14 non-CAKUT vs. CAKUT ESRD etiologies and under stratification by estimated glomerular filtration rate (eGFR).
RESULTS
Among 25,761 patients, the median (interquartile range) age was 17 (11-19) years, and 4780 (19%) had CAKUT. CAKUT was associated with lower mortality, with an adjusted hazard ratio (aHR) of 0.72 (95%CI, 0.64-0.81) (reference: non-CAKUT). In age-stratified analyses, CAKUT vs. non-CAKUT aHRs (95%CI) were 0.66 (0.54-0.80), 0.56 (0.39-0.80), 0.66 (0.50-0.86), and 0.97 (0.80-1.18) among patients < 6, 6-< 13, 13-< 18, and ≥ 18 years at dialysis initiation, respectively. Among non-CAKUT ESRD etiologies, the risk of mortality associated with primary glomerulonephritis (aHR, 0.93; 95%CI 0.80-1.09) and focal segmental glomerulosclerosis (aHR, 0.89; 95%CI, 0.75-1.04) were comparable or slightly lower compared to CAKUT, whereas most other primary causes were associated with higher mortality risk. While the CAKUT group had lower mortality risk compared to the non-CAKUT group patients with eGFR ≥5 mL/min/1.73m
CONCLUSIONS
CAKUT is associated with lower mortality among children < 18 years old, but showed comparable mortality with non-CAKUT among patients ≥ 18 years old. ESRD etiology should be considered in risk assessment for children initiating dialysis.

Identifiants

pubmed: 32020338
doi: 10.1007/s00467-019-04457-7
pii: 10.1007/s00467-019-04457-7
pmc: PMC8876253
mid: NIHMS1556607
doi:

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

851-860

Subventions

Organisme : NIDDK NIH HHS
ID : K24 DK091419
Pays : United States
Organisme : NIDDK NIH HHS
ID : R03 DK114642
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK102163
Pays : United States
Organisme : NIDDK NIH HHS
ID : K23 DK102903
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK104687
Pays : United States

Références

Am J Kidney Dis. 2005 Nov;46(5):887-96
pubmed: 16253729
Kidney Int. 2009 Sep;76(5):528-33
pubmed: 19536081
Pediatr Nephrol. 2007 Dec;22(12):1999-2009
pubmed: 17310363
PeerJ. 2018 Jul 27;6:e5284
pubmed: 30065880
Epidemiology. 2009 Jul;20(4):488-95
pubmed: 19525685
Kidney Int. 2016 Mar;89(3):512-8
pubmed: 26880442
Pediatr Nephrol. 2012 Oct;27(10):1975-83
pubmed: 22673972
Pediatr Nephrol. 2008 Nov;23(11):2039-46
pubmed: 18560903
N Engl J Med. 2004 Jun 24;350(26):2654-62
pubmed: 15215481
J Pediatr. 1984 Jun;104(6):849-54
pubmed: 6726515
Clin J Am Soc Nephrol. 2010 Nov;5(11):2046-52
pubmed: 20688886
Pediatr Nephrol. 2010 Jun;25(6):1153-61
pubmed: 20191370
J Am Soc Nephrol. 2009 Mar;20(3):629-37
pubmed: 19158356
JAMA. 2006 Jul 26;296(4):421-6
pubmed: 16868300
Nephrol Dial Transplant. 2011 Dec;26(12):3843-51
pubmed: 22121240
Nephrol Dial Transplant. 2009 Oct;24(10):3175-82
pubmed: 19515803
Pharm Stat. 2011 Mar-Apr;10(2):150-61
pubmed: 20925139
Am J Kidney Dis. 1998 Jul;32(1):72-9
pubmed: 9669427
Pediatr Nephrol. 2016 Dec;31(12):2317-2325
pubmed: 27761660
Clin J Am Soc Nephrol. 2013 Jan;8(1):67-74
pubmed: 23085722
Kidney Int. 2015 Sep;88(3):605-13
pubmed: 25874598
Stat Med. 2009 Nov 10;28(25):3083-107
pubmed: 19757444
Singapore Med J. 1991 Oct;32(5):304-6
pubmed: 1788570
Perit Dial Int. 2005 Feb;25 Suppl 3:S120-2
pubmed: 16048275
Pediatr Nephrol. 2015 Sep;30(9):1501-9
pubmed: 25794549
Pediatr Nephrol. 2009 Sep;24(9):1719-26
pubmed: 19373494
Pediatr Nephrol. 1997 Jun;11(3):302-6
pubmed: 9203177
Pediatr Nephrol. 2012 Mar;27(3):363-73
pubmed: 21713524
JAMA. 2013 May 8;309(18):1921-9
pubmed: 23645144
Lupus. 2012 Oct;21(11):1208-13
pubmed: 22736748
N Engl J Med. 2018 Feb 1;378(5):428-438
pubmed: 29385364
Am J Kidney Dis. 2017 May;69(5):617-625
pubmed: 27955924
Am J Kidney Dis. 2010 Aug;56(2):348-58
pubmed: 20605303
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Am J Kidney Dis. 2019 Jun;73(6):797-805
pubmed: 30833086
Clin J Am Soc Nephrol. 2012 Dec;7(12):1969-76
pubmed: 22997344
Clin J Am Soc Nephrol. 2014 Feb;9(2):302-9
pubmed: 24262507

Auteurs

Yusuke Okuda (Y)

Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine Medical Center, 101 The City Drive South, City Tower, Suite 400, Orange, CA, 92868, USA.
Department of Pediatrics, Kitasato University School of Medicine, 1 Chome-15-1 Kitazato, Minami Ward, Sagamihara, Kanagawa, 252-0374, Japan.

Melissa Soohoo (M)

Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine Medical Center, 101 The City Drive South, City Tower, Suite 400, Orange, CA, 92868, USA.

Kenji Ishikura (K)

Department of Pediatrics, Kitasato University School of Medicine, 1 Chome-15-1 Kitazato, Minami Ward, Sagamihara, Kanagawa, 252-0374, Japan.

Ying Tang (Y)

Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine Medical Center, 101 The City Drive South, City Tower, Suite 400, Orange, CA, 92868, USA.

Yoshitsugu Obi (Y)

Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine Medical Center, 101 The City Drive South, City Tower, Suite 400, Orange, CA, 92868, USA.

Marciana Laster (M)

David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Division of Pediatric Nephrology, Mattel Children's Hospital at UCLA, 757 Westwood Plaza, Los Angeles, CA, 90095, USA.

Connie M Rhee (CM)

Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine Medical Center, 101 The City Drive South, City Tower, Suite 400, Orange, CA, 92868, USA.

Elani Streja (E)

Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine Medical Center, 101 The City Drive South, City Tower, Suite 400, Orange, CA, 92868, USA.

Kamyar Kalantar-Zadeh (K)

Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine Medical Center, 101 The City Drive South, City Tower, Suite 400, Orange, CA, 92868, USA. kkz@uci.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH